New weight loss drugs aim to save muscle
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate additional health benefits beyond the numbers on a scale to get approved.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Veru Inc (NASDAQ:VERU) is set to release its Q1 2025 earnings on Feb 13, 2025. The consensus estimate for Q1 2025 revenue is ...
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...
Enobosarm + semaglutide reduced lean mass loss by 71% and increased fat mass loss by 27% vs. Wegovy alone. Phase 2b extension trial to assess weight loss maintenance is ongoing, with results ...
Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...
Gladstone Institutional Advisory LLC lifted its position in Veru Inc. (NASDAQ:VERU – Free Report) by 52.7% in the 4th quarter, according to the company in its most recent filing with the Securities ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback